

Diagnostic Role of Circulating Exosomal microRNA-1286 for the progression of Colorectal Cancer

Gul e Nasreen¹, Awais Altaf^{1,2*}, Zainab Javaid³, Tahir Maqbool^{1*}, Ali Amar^{4,5}, Syed Mohsin Raza Bokhari⁵

ABSTRACT

OBJECTIVE: To assess the expression and clinical significance of exosomal miR-1286 for the detection and progression of CRC.

METHODOLOGY: miR-1286 was selected using the GEO dataset GSE39833. Bioinformatics tools were used to analyze its expression in CRC. After the collection of serum samples using the double centrifugation technique from 23 CRC patients, exosomal enrichment was performed, and miRNA extraction was done. After reverse transcription of the RNA template, its expression level was analyzed by qRT-PCR (Quantitative Reverse Transcription Polymerase Chain Reaction). miR-1286 expression levels correlated with colorectal cancer clinical characteristics, and patient survival was further examined using Kaplan-Meier analysis.

RESULTS: miRNA-1286 was found to be non-significant in comparing T3 and T4, N1 and N2 stages, and in discriminating colorectal metastatic tumor patients from non-metastatic tumor patients (p -value >0.05). ROC (Receiver Operating Characteristic) curve analysis revealed an AUC (Area under the Curve) of 0.69 with 75% sensitivity and 83.3% specificity at the cut-off value of > 1.07 .

CONCLUSION: Upregulated expression of miR-1286 in colorectal cancer is not statistically significant enough to be used as a diagnostic biomarker for the detection and progression of CRC.

KEYWORDS: miRNAs, colorectal carcinoma, CRC, Exosome, real-time PCR, Exosomal miRNA

INTRODUCTION

Colorectal cancer is becoming a global threat. This is the second deadliest after lung cancer, the 3rd most common cancer, and accounts for 10% of all malignancies. With an annual incidence of 1.93 M cases in 2020, it is one of the most studied neoplasms. Its predicted rise in prevalence over the next two decades makes this a serious concern. Recent years have shown an alarming rise in CRC prevalence in high HDI (Human Development Index) countries, with more than 40 incidents per 100,000 people and 935,000 fatalities predicted for 2020. The age-standardized mortality rate (ASMR) for colorectal cancer (CRC) is roughly 8.9 per 100,000 people worldwide. The 5-year survival rate for stage IV cancer is 14%, in contrast with stage I CRC, which accounts for roughly 90%¹.

CRC causes altered bowel habits, bleeding per rectum, abdominal pain or mass, weight loss,

microcytic hypochromic anemia, anorexia, and deep vein thrombosis. Western lifestyle adoption, obesity, red meat consumption, alcohol intake, sedentary lifestyle, and smoking are risk factors for CRC, which is rising rapidly in emerging nations. A strong family history is associated with a younger CRC diagnosis, especially in proximal colonic cancer compared to rectal cancer².

In Pakistan, the WHO reports a steady rise in cancer rates. With 30% of the population elderly and 20% adults, 43% of middle-aged people were most at risk, with male predominance (men, 54%; women, 46%). CRC is most common in Sindh and among Urdu-speaking males, followed by Baloch, Punjabi, and Pakhtoon males, and least common among Siraiiki males³. According to the 2021 annual cancer registry data from Shaukat Khanum Memorial Hospital, colon cancer accounts for 7.7% of all malignancies and is the second most common cancer in Pakistan after breast cancer⁴.

DRE (digital rectal examination), FIT (faecal immunochemical test) for hemoglobin, gFOBT (Guaiac faecal occult blood test), flexible sigmoidoscopy, and optical colonoscopy are used to diagnose CRC. Because gFOBT is not specific to human hemoglobin, certain foods and medications can cause false positives. NICE recommends FIT (which detects human-specific hemoglobin in feces) for suspected CRC with bowel habit changes, iron-deficient anemia, or at age 60. Endoscopic tumour identification, sample collection, and gut examination after patient preparation determine the diagnosis⁵. Validated biomarkers that are minimally invasive,

¹Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan

²Faculty of Health Sciences, Equator University of Science and Technology, Masaka, Uganda

³Faryal Dental College, Lahore, Pakistan

⁴Institute of Nursing and Allied Health Sciences, Pakistan Kidney and Liver Institute and Research Center (PKLI and RC), Lahore, Pakistan

⁵Institute of Allied Health Sciences, University of Health Sciences, Lahore, Pakistan

Correspondence: awaisaltaf362@yahoo.com;

tahir.maqbool@imbb.uol.edu.pk

doi: 10.22442/jlumhs.2026.01292

Received: 14-04-2025

Revised: 06-04-2026

Accepted: 14-04-2026

Online First: 01-06-2026



accurate, and enable early detection and prognostic prediction of CRC are needed. MicroRNAs, evolutionarily conserved short non-coding RNAs of 18-25 nucleotides, regulate cellular and pathogenic processes via diverse pathways⁶.

Because of their serum and plasma stability, circulating miRNAs are considered blood-based biomarkers. This study assessed miR-1286 expression as an early CRC diagnostic and prognostic biomarker and related it to the clinicopathological characteristics of CRC patients. For this study, miR-1286 expression was evaluated to correlate with different stages of CRC to deduce the disease at its early stages, prognosis, and treatment response.

METHODOLOGY

This cross-sectional study included subjects aged 20-70 years. The three groups were C Group 1 (Healthy normal individuals), T Group 1 (Non-metastatic colorectal cancer blood sample), and T Group 2 (Metastatic). The study's process, risks, and benefits were described to participants who provided consent.

Subject Selection and Recruitment

Over 6 months, we enrolled 23 patients (10 non-metastatic and 13 metastatic) with histopathologically confirmed CRC diagnoses from Nishtar Hospital, Multan. To meet inclusion and exclusion criteria, all CRC patients were treatment-naïve and had not had any cancer treatment, including chemotherapy or radiotherapy. Healthy controls were 10 people without benign or malignant tumours or chronic systemic illnesses.

Pilot in silico analysis

Data mining of exosome datasets

Four public databases, i.e., Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>), Expression Atlas (<https://www.ebi.ac.uk/gxa/>), ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>), and the Genomic Expression Archive (GEA, <https://www.ddbj.nig.ac.jp/gea/>) were searched for exosome-based miRNA gene expression datasets of colorectal cancer. These public datasets were searched with keywords such as "colorectal carcinoma", "colorectal cancer", "rectal cancer", "colon cancer", "exosomes", "exosome", "exosomal", "miRNA", and "microRNA". A set of criteria was used to filter the datasets.

Pre-processing and differential expression

R software was used to extract RAW Agilent microarray image files of miRNA expression from GEO datasets. Background correction using the "normexpr" method and normalization through the "quantile" method were conducted for each array. Background-adjusted and normalized data were analyzed to remove signals from control, negative, and low-expressed probes. We used RLE plots, boxplots, heatmaps, hclust clustering plots, and PCA plots to ensure data quality. To reduce within-sample outlier variance, the "limma" R package calculated array weights for each array, and the "lmfit" and "eBayes" algorithms estimated overall and within-

stage contrast-based differential expression. Differential significance was determined using FDR-adjusted $p < 0.05$ and $|\log FC| > 1$.

Selection of miRNA for the current study

The study systematically analyzed differentially expressed miRNAs, identified those not previously studied for their potential as biomarkers, and selected "has-miR-1286" miRNA with a logFC value of 7.89 based on its significant differences in public literature databases.

Sample Collection

We collected samples from CRC patients and healthy subjects at Nishtar Hospital, Multan, after approval from the IMBB/University of Lahore ethical review committee (letter no. Ref-IMBB/BBBC/23/186-A, dated February 15, 2023). The study was further processed at the University of Health Sciences, Kala Shah Kaku Campus, Lahore.

Screening of Subjects

Biochemical and hematological parameters were used to screen suspected CRC patients and healthy subjects, including Hemoglobin, Total leukocyte count, and Carcinoembryonic antigen.

Histopathology-based confirmation of CRC and Staging

The study included all stages of suspected cases confirmed by histopathology after colonoscopy and grouped according to WHO criteria.

Study data collection

Demographic (i.e., age and gender) and clinicopathologic (hematological and biochemical parameters, tumor stage, nodal involvement, and distant metastases) data of CRC patients were recorded using a dedicated proforma.

Sample Size

The study had 90% power, a 5% significance level, a logFC of 7.89, and a ΔCt standard deviation of ΔCt of 2. A sample size of 2 was calculated for each group using the formula from the Statistical Rules of Thumb. 13 samples were selected from the metastatic group, 10 from the non-metastatic group, and 10 from the healthy control group for better results.

Serum separation and storage for miRNA analysis

Blood samples were collected from the CRC patients (before any treatment) and healthy control subjects in serum vacutainer tubes (BD, USA) and centrifuged for serum separation and divided into aliquots of 1 mL and frozen at -20°C for subsequent processing for exosome and RNA purification. For RNA purification, we thawed the frozen serum completely by incubating it in a 37°C water bath.

Exosomal Enrichment

Invitrogen™ Total Exosome Isolation Reagent (from serum; catalogue number 4478360) was used for extract exosomes according to the instructions.

miRNA Isolation

We isolated miR-1286 from CRC and healthy control serum samples using the FavorPrep™ miRNA Isolation kit according to the described protocol.

cDNA Synthesis

cDNA was synthesized using miRcute Plus miRNA First-Strand cDNA Kit following the prescribed protocol. 2×miRNA RT Reaction Buffer, RNA Template, and RNase-free ddH₂O were thawed fully and transiently centrifuged, and all of them were put on ice. All the steps were performed on ice.

Expression analysis by real-time PCR

miRNA sequence (www.mirbase.org) based primers were synthesized commercially by Macrogen.

Table I: Target microRNA Sequences

Sr#	Item	Specifications
1	RT primer (universal)	CAGTGCAGGGTCCGAGGTCAGAGCCAC-CTGGGCAATTTTTTTTTTVN
2	Reverse primer for qPCR (universal)	CAGTGCAGGGTCCGAGGT
3	FP_ has miR-1286	UGCAGGACCAAGAUGAGCCCU
4	FP_ hsa-RNU6-1	CGCTTCGGCAGCACATATACTA

miR-1286 was amplified by real-time PCR using miRcute Plus miRNA qPCR Kit (SYBR green). The expression results of real-time PCR were measured and compared using various analyses.

Statistical Analysis

Data were entered and analyzed using IBM SPSS statistical software version 26 (The IBM® SPSS® software) and GraphPad Prism software 8.0 USA. Shapiro-Wilk and Kolmogorov-Smirnov tests were used to assess the normality of the data. A *p*-value of < 0.05 was considered significant. Frequencies and percentages were used for qualitative variables (age, gender, TNM stage, tumor invasion (T), tumor nodules (N), metastasis, tumor localization, histological grading of tumor, and patient survival status). Quantitative variables were expressed as mean (± SD) values: carcinoembryonic antigen (CEA), Haemoglobin (Hb), and Total leukocyte count (TLC). The independent t-test was used to assess the association of miRNA with age, gender, TNM stage, tumor invasion (T), tumor nodules (N), metastasis, tumor localization, histological grading of tumor, and patient survival status. For different comparison groups (e.g., CRC patients at different stages and healthy subjects), we calculated normalized miRNA expression values and compared them using the 2-ΔΔCt method. An unpaired t-test was used to compare stage III with stage IV (non-metastatic versus metastatic), and to compare stages N1 and N2, and stage T3 and stage T4. A receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic accuracy, specificity, sensitivity, and area under the curve (AUC) of dysregulated miRNA-1286.

RESULTS

Cohort characteristics

This study included a cohort of 33 Pakistani CRC patients. Demographic, clinicopathological, therapeutic, and Survival characteristics, along with

their association with CRC serum microRNA-1286 levels, indicated that miR-1286 was not significantly associated with stage T1-T, N0-N1 histological grading, or metastasis in CRC samples, as shown in Table II.

Table II: Baseline demographic and clinicopathological features and their association with CRC serum microRNA-1286 levels of Pakistani CRC patients

Characteristics	CRC patients (n =33)	miR-1286 (mean ± SD)
Demographic		
Age in years (Mean ± SD)	51 (21-72)	
Age ≤50 years	09 (39.1 %)	6.64±1.26
Age >50 years	14 (60.9 %)	5.96±0.62
<i>p</i> -value		0.58
Gender, n=23 (%)		
Female	11 (47.8%)	6.09±0.77
Male	12 (52.2%)	6.06±0.77
<i>p</i> -value		0.94
Clinicopathological		
cT stage, n=23(%)		
T1-T2	02 (8.7%)	0
T3-T4	21 (91.3%)	6.07±0.73
<i>p</i> -value		-
cN stage, n=23 (%)		
NX-N0	03 (13%)	0
N1-N2	20 (87%)	6.06±0.73
<i>p</i> -value		-
Overall TNM stage, n=23 (%)		
I-II	03 (13%)	0
III-IV	20 (87%)	6.07±0.73
<i>p</i> -value		-
Histological grading, n=23 (%)		
Well-differentiated	04 (17.4%)	5.92±0.75
Moderately differentiated	09 (39.1%)	
Poorly differentiated	10 (43.5%)	6.18±0.75
<i>p</i> -value		0.56
Tumor localization, n=23(%)		
Colon	10 (43.5%)	5.99±0.59
Rectum	13 (56.5%)	6.13±0.85
<i>p</i> -value		0.740
Tumor metastasis, n=23(%)		
No	09 (39.1%)	6.67±0.45
Yes	14 (60.9%)	5.95±0.72
<i>p</i> -value		0.18
Laboratory		
Median Carcinoembryonic Antigen (CEA)	105.4	
Mean Hemoglobin (Hb)	9.37±1.72	
Mean Total leucocyte count (TLC)	10.04±1.05	
Survival		
Overall Survival in months, n = 23, Median (Range) 12		
Survival status, n (%)		
Alive	21 (91.3%)	6.22±0.70
Dead	02 (8.7%)	5.34±0.18
<i>p</i> -value		0.009
miRNA levels		
Mean miR-1286	6.08	

TNM: Tumor Node, and Metastasis; cT: Tumour; cN: Node

Table III: Expression analysis of miR-1286 in CRC serum samples

ROC Analysis of serum microRNA-1286 to segregate CRC patients from healthy controls

AUC	95% CI	Cut-off	Sensitivity	Specificity	p-value
0.69	0.43-0.96	>1.07	75	83.33	0.19

Normalized mean expression levels of microRNA-1286 and the fold change in CRC patients versus healthy controls

No. of samples	Healthy control (mean $\pm$ SD)	CRC (mean $\pm$ SD)	Fold change	p-value
HC n= 6 CRC n= 12	1.07	1.52	1.42	0.15

Comparison of miR-1286 expression in stage T3 and stage T4

No. of samples	T3 (mean $\pm$ SD)	T4 (mean $\pm$ SD)	p-value
T3 n=04 T4 n=09	6.24 $\pm$ 0.74	6.02 $\pm$ 0.76	0.67

Comparison of miR-1286 expression in stages N1 and N2

No. of samples	N1 (mean $\pm$ SD)	N2 (mean $\pm$ SD)	p-value
N1 n=08 N2 n=03	5.82 $\pm$ 0.36	6.01 $\pm$ 0.66	0.61

Comparative analysis of miR-1286 expression in metastatic and non-metastatic CRC patients

No. of samples	Stage III (mean $\pm$ SD)	Stage IV (mean $\pm$ SD)	p-value
Stage III n=03 Stage IV n=09	6.30 $\pm$ 0.74	5.99 $\pm$ 0.75	0.55

AUC: Area under curve; SD: Standard Deviation; HC: Healthy control; CRC: Colorectal carcinoma




Figure 1: Expression analysis of miR-1286 in Colorectal cancer patients and normal serum samples; A: Relative expression level of microRNA-1286 in CRC and normal serum samples; B: Diagnostic values of serum microRNA-1286 in CRC patients; C: MicroRNA-1286 Expression in stage T3 and stage T4; D: Comparison of miR-1286 expression in stage N1 and N2; E: Comparative analysis of miR-1286 expression in metastasis vs. non-metastasis in CRC patients; F: Kaplan Meier survival curve for Overall Survival

CRC: colorectal carcinoma; TNM: Tumor Node and Metastasis

Expression analysis of miR-1286 in CRC serum samples

The study evaluated miRNA-1286 expression as a minimally invasive biomarker for colorectal cancer progression in 18 serum samples, using the $2^{-\Delta\Delta C_t}$ quantitative approach and found no statistically non-significant difference, indicating that miR-1286 was not significantly expressed in CRC patient serum.

The study evaluated the diagnostic potential of miR-1286, which was not significant in distinguishing colorectal cancer patients from healthy controls. Candidate microRNA-1286 was found to be non-significant in comparing T3 and T4, N1 and N2 stages and in discriminating colorectal metastatic tumor patients from non-metastatic tumor patients (p -value >0.05), as mentioned in **Table III** and **Figure 1**.

Kaplan-Meier survival curves for Overall Survival

The study analyzed follow-up data for 23 patients, with 8.7% dying due to CRC. The median Survival was 12 months, and the Kaplan-Meier survival curve showed undefined overall Survival for $n=06$ patients, with both low and high serum miR-1286 levels above 50%.

DISCUSSION

Colorectal cancer is spreading worldwide. CRC is expected to be a monster by 2040, especially in countries with high or very high HDI, as it accounts for 10% of all malignancies, which are the second most deadly, third most diagnosed, and most studied neoplasms. Men get colon cancer more than women⁷. Young patients most often have rectal type and stage III⁸. In age groups >50 and 40, a strong family history of CRC alone or with diabetes mellitus increases risk. CRC risk increases with obesity, alcohol, tobacco, and inactivity⁹. This study found no significant differences in laboratory biochemical profiles among CRC patients. DRE, FIT, gFOBT, flexible sigmoidoscopy, optical colonoscopy, MRI, CTC, FAPI-PET, and DW-MRI are utilized to diagnose colorectal cancer¹⁰. However, CEA and CA19-9 are predictive and prognostic blood biomarkers, but these methods are not sufficient for accurate, early diagnosis¹¹. A tumor forms when persistent DNA mutations prevent apoptosis¹². Furthermore, the majority of patients would be treated if this massive cancer were found and removed in a precancerous stage, since most colorectal cancers proceed along the serrated pathway or a slow adenoma-carcinoma cascade¹³. Thus, detecting early colorectal neoplasms, including precancerous lesions, is crucial to minimizing colorectal cancer mortality. Data suggest that lymph node metastases may predict disease-free and overall Survival in colorectal cancer patients without distant metastasis¹⁴. Early tumor detection improves survival rates in CRC patients, underscoring the need for precise, sensitive, and non-aggressive molecular biomarkers¹⁵. Early detection and treatment of metastatic colorectal cancer may help patients who have relapsed recover¹⁶. miRNA-encoding genes are widely distributed across the genome; therefore, their

transcription could be coordinated with that of protein-coding genes. Certain miRNAs have oncogenic properties that influence cell proliferation and other cancer-associated biological processes. Some hypotheses suggest miRNAs can diagnose and prognose cancer¹⁷. Growing research shows that miRNAs are essential to the formation and progression of human tumors, making them promising biomarkers for cancer diagnosis, prognosis, and treatment. Although miRNAs may serve as screening biomarkers, functional prediction analysis is needed to understand their role in CRC carcinogenesis¹⁸. Alves dos Santos K et al¹⁹ found that exosomal miRNAs modulate the immune system, chemoresistance, and metastasis in diverse tumors. Exosomes enable CRC cells to release miRNAs into the extracellular environment regardless of their intracellular expression levels. miRNA profiles have been generated using flow cytometry, microarrays, and cationic lipoplex nanoparticles. However, qRT-PCR remains the favored method because of its excellent sensitivity and specificity²⁰. Due to their high sensitivity and specificity, miRNAs can differentiate CRC patients from normal tissue in a minimally invasive manner²¹. Despite a 75% sensitivity and 83.33% specificity, miR-1286 was not a diagnostic marker in this investigation. CircCOL1A2 sponges miR-1286, regulating gastric cancer cell invasion and migration²². Overexpression of miR1286 through MAFB downregulation inhibits osteosarcoma cell growth. Mechanism-enhancing head and neck squamous cell cancers and osteosarcoma involve miR1286²³. In GC, miR-1286 behaved as a tumor suppressor and biomarker and was strongly linked to HP infection and the emergence of peritoneal metastases²⁴. A study found that miR-1286 inhibits NSCLC proliferation through aerobic glycolysis, making it a potential biomarker²⁵. MiR-1286 was not previously studied in CRC. A magnitude difference of 1.42 fold change of elevated miR-1286 in CRC samples did not correlate with normal serum samples in this investigation. Demographic, clinical, and pathological associations of miR-1286 were not significant. Two-fifths of miRNAs were not significantly expressed in tumors versus non-tumors. Given that many colon cancer cases are identified at stage T3, the prognosis is unpredictable due to high variability. Many limitations plagued this study. First, clinical samples were few. Stage I samples were unavailable, and only a small number of Stage II samples were available. MicroRNAs for CRC detection and progression need further study. While more work is needed, we remain confident that microRNA-related diagnostics and treatments have considerable potential for prognostic prediction and treatment of CRC.

CONCLUSION

In our study, we found that CRC affects all ages. A considerable percentage of patients were diagnosed after age of 50, and it is more prevalent in older

adults. This aligns with the documented pattern of increasing CRC risk with age. Given the high proportion of advanced-stage patients, early identification methods, such as screening, may be crucial to improving patient outcomes. This significant fold change (FC) of 1.42 in miRNA-1286 expression in CRC patients compared with healthy controls prompted us to assume a correlation with a disease process. The mean normalized expressions of the two groups were not statistically different. At the cut-off value, miRNA-1286 had good AUC, sensitivity, and specificity. Except for histological grading, in which a greater percentage of patients reported having poorly differentiated, advanced cancer and higher levels of miRNA, the miRNAs did not show any substantial relationships. When using miRNA expression to predict severity, stage III and stage IV colorectal cancer patients show aberrant miRNA-1286 expression. No clear distinction in miRNA expression was observed between metastatic and non-metastatic patients. MiRNA expression did not differ between T3 and T4 colorectal cancer patients, despite the expected misexpression of miRNA-1286. Overall survival analysis was not significant, as individuals with high and low serum levels had similar survival curves above 50%. Few prospective miRNA panels as CRC biomarkers are needed to improve disease prediction. Reflective circulating miRNAs can be increased by minimally invasive screening.

Ethical Permission: University of Lahore, Lahore, Pakistan, ERC approval letter No. IMBB/BBBC/23/186 -A.

Conflict of interest: There is no conflict of interest between the authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Nasreen G: Performed the experiments and wrote the original draft

Altaf A: Supervised and administered the entire project

Javaid Z: Assisted with experimentation and manuscript preparation

Maqbool T: Validated the results and proofread the manuscript

Amar A: Facilitated experimentation and data analysis

Bokhari SMR: Provided support for bioinformatics analysis.

REFERENCES

1. Matsuda T, Fujimoto A, Igarashi Y. Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies. *Digestion*. 2025.
2. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. *Cancer J Clinicians*. 2022 Jul; 72(4): 372-401.
3. Khaliq SA, Fatima A, Siddiqui MG, Sheikh M, Zaib -Un-Nisa A. Point prevalence of colorectal cancer in a megacity of Pakistan, Karachi – A cross-sectional study. *Univ J Pharmaceut Res*. 2023 May 15.
4. Ibrar F, Atiq M, Shafqat F, Khan HM. Early-onset Colorectal Cancer and its association with its histological subtypes. *Pak J Med Sci*. 2024 Nov; 40(10): 2395.
5. Issa IA, Nouredine M. Colorectal cancer screening: An updated review of the available options. *World J Gastroenterol*. 2017 July 28; 23(28): 5086.
6. Ghafouri-Fard S, Hussien BM, Badrlou E, Abak A, Taheri M. MicroRNAs as important contributors in the pathogenesis of colorectal cancer. *Biomed Pharmacother*. 2021 August 1; 140: 111759.
7. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. *Transl Oncol*. 2021 Oct 1; 14(10): 101174.
8. Raj S, Kishor K, Devi S, Sinha DK, Madhawi R, Singh RK et al. Epidemiological trends of colorectal cancer cases in young population of Eastern India: A retrospective observational study. *J Cancer Res Therapeut*. 2023 May 25.
9. Boyle T, Fritschi L, Tabatabaei SM, Ringwald K, Heyworth JS. Smoking, alcohol, diabetes, obesity, socioeconomic status, and the risk of colorectal cancer in a population-based case-control study. *Cancer Causes & Control*. 2014 Dec; 25: 1659-68.
10. Sawicki T, Ruskowska M, Danielewicz A, Niedzwiedzka E, Arlukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. *Cancers*. 2021 Apr 22; 13(9): 2025.
11. Lakemeyer L, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. *Diseases*. 2021 Mar 17; 9(1): 21.
12. Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: do they threaten the Survival of the FIT test? *Digestive Diseases and Sciences*. 2015 Mar; 60: 664-71.
13. Zhang Y, Wang Y, Zhang B, Li P, Zhao Y. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer. *Biomed Pharmacother*. 2023 Jul 1; 163: 114786.
14. Holch JW, Demmer M, Lamersdorf C, Michl M, Schulz C, von Einem JC, Modest DP, Heinemann V. Pattern and dynamics of distant metastases in metastatic colorectal cancer. *Visceral Medicine*. 2017 Mar 14; 33(1): 70-5.
15. Zhou K, Liu M, Cao Y. New insight into microRNA functions in cancer: oncogene-microRNA-tumor

- suppressor gene network. *Front Mol Biosci.* 2017 Jul 7;4: 46.
16. Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study. *JAMA Oncology.* 2024 Jan 1; 10(1): 54-62.
17. Yaghoubi N, Avval FZ, Khazaei M, Aghaee-Bakhtiari SH. MicroRNAs as potential investigative and predictive biomarkers in colorectal cancer. *Cellular Signalling.* 2021 April 1; 80: 109910.
18. Mohamed SS, Ahmad A, Ab Mutalib NS, Tengku TA, Salleh MS, Zakaria AD et al. A panel of three MicroRNA signatures as a potential biomarker for CRC screening based on stages and functional prediction using bioinformatic analysis. *Progress In Microbes & Molecular Biology.* 2023 Aug 31; 6 (1).
19. Alves dos Santos K, Clemente dos Santos IC, Santos Silva C, Gomes Ribeiro H, de Farias Domingos I, Nogueira Silbiger V. Circulating exosomal miRNAs as biomarkers for the diagnosis and prognosis of colorectal cancer. *Int J Mol Sci.* 2020 December 31; 22(1): 346.
20. Shi Y, Zhuang Y, Zhang J, Chen M, Wu S. Four circulating exosomal miRNAs as novel potential biomarkers for the early diagnosis of human colorectal cancer. *Tissue and Cell.* 2021 June 1; 70: 101499.
21. Sun K, Wang W, Zeng JJ, Wu CT, Lei ST, Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. *Acta Pharmacologica Sinica.* 2011 Mar; 32(3): 375-84.
22. Li H, Chai L, Ding Z, He H. CircCOL1A2 sponges MiR-1286 to promote cell invasion and migration of gastric cancer by elevating expression of USP10 to downregulate RFC2 ubiquitination level. *J Microbiol Biotechnol.* 2022 May 11; 32(7): 938.
23. Huang Z, Chen P, Jia R, Liu Y. Circ_0051079 functions as an oncogenic regulator in osteosarcoma by leading to MAFB expression upregulation by competitively interacting with miR-1286. *J Orthop Surg Res.* 2022 September 24;17 (1): 428.
24. Tian M, Jiang M, Bi Y, Wang B. miR-1286, a Tumor Suppressor of Gastric Cancer, Serves as a Promising Biomarker for Screening Gastric Cancer from Gastritis. *Biochemical Genetics.* 2024 Oct; 62(5): 3761-73.
25. Li H, Lin X, Li C, Li J, Xu X, Meng D et al. MiR-1286 inhibits lung cancer growth through aerobic glycolysis by targeting PKM2. *Arch Med Sci.* 2019 September 18; 19(1): 151.

